Table 4 Comparison of demographic data between PM/DM-ILD patients with or without complication of serious infection^a (excerption^b)

24/38 (63.2%)

59/78 (75.6%)

0.16

PM 7, DM 24, CADM 7

PM 15, DM 27, CADM 36

0.007**

58.9 ± 13.9^c

54.7 ± 15.2^c

0.15

Baseline data

LDH (U/l)

420 (335–574)^d

343 (258–486)^d

0.005**

KL-6 (U/ml)

848 (605–1231)^d

572 (405–978)^d

0.014*

CRP (mg/dl)

0.9 (0.34–1.99)^d

0.30 (0.10–1.51)^d

0.032*

Lymphocyte (/μl)

848 (552–1177)^d

1,008 (735–1435)^d

0.040*

Albumin (g/dl)

3.18 ± 0.52^c

3.53 ± 0.55^c

0.003**

PaCO₂ (mmHg)

36.0 (31.5–38.8)^d

38.0 (35.5–41.5)^d

0.016*

HRCT

Zone A

1.0 (0–2.0)^d

1.0 (0–1.0)^d

0.054

Zone B

1.0 (1.0–2.0)^d

1.0 (0–1.0)^d

0.049*

Zone C

2.0 (1.0–3.0)^d

1.0 (1.0–2.0)^d

0.036*

Zone D

3.0 (2.0–4.0)^d

3.0 (2.0–4.0)^d

0.068

Zone total

7.0 (4.0–11.0)^d

6.0 (4.0–8.0)^d

0.031*

Treatment (n (%))

Initial PSL dose (mg/kg/day)

0.94 ± 0.30^c

0.76 ± 0.29^c

0.005**

mPSL pulse (n (%))

31/38 (81.6%)

46/78 (59.0%)

0.016*

IVCY (n (%))

25/38 (65.8%)

23/78 (29.5%)

<0.001**

Calcineurin inhibitor

34/38 (89.5%)

47/77 (61.0%)

0.002**

Combination therapy^e

23/38 (60.5%)

17/78 (21.8%)

<0.001**

Outcome (n (%))

Death

11/38 (28.9%)

3/78 (3.8%)

<0.001**